Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 1,030,000 shares, a decrease of 14.2% from the December 15th total of 1,200,000 shares. Currently, 1.8% of the company’s stock are short sold. Based on an average daily volume of 131,000 shares, the short-interest ratio is presently 7.9 days.

Nautilus Biotechnology Trading Down 2.1 %

NAUT stock opened at $1.90 on Friday. The firm has a market capitalization of $238.56 million, a PE ratio of -3.39 and a beta of 1.20. Nautilus Biotechnology has a 1-year low of $1.61 and a 1-year high of $3.12. The business’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $2.43.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. During the same period last year, the business earned ($0.13) EPS. As a group, sell-side analysts predict that Nautilus Biotechnology will post -0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group lowered Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NAUT. Dimensional Fund Advisors LP grew its holdings in Nautilus Biotechnology by 19.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after buying an additional 94,908 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Nautilus Biotechnology by 11.2% in the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after buying an additional 14,100 shares in the last quarter. SG Americas Securities LLC acquired a new position in Nautilus Biotechnology in the 3rd quarter valued at $50,000. China Universal Asset Management Co. Ltd. grew its holdings in Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock valued at $69,000 after buying an additional 9,404 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Nautilus Biotechnology in the 3rd quarter valued at $67,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.